Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons

@article{Liu2013GlimepirideAA,
  title={Glimepiride attenuates A$\beta$ production via suppressing BACE1 activity in cortical neurons},
  author={Fei Liu and Yijin Wang and Ming Yan and Luyong Zhang and Tao Pang and Hong Liao},
  journal={Neuroscience Letters},
  year={2013},
  volume={557},
  pages={90-94}
}
Numerous lines of evidence suggest a strong link between diabetes mellitus and Alzheimer's disease (AD). Impaired insulin signaling and insulin resistance occur not only in diabetes but also in the brain of AD. Recent evidence has indicated that peroxisome proliferator-activated receptor γ (PPARγ) agonists thiazolidinediones (TZDs) can decrease β-amyloid peptide (Aβ) deposition, which is the core component of senile plaques in AD, but the underlying mechanisms still remain unclear. In this… Expand
Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer’s Disease Through Inhibition of BACE1
TLDR
In vivo and in vitro, AS-IV treatment increased PPARγ and BACE1 expression and reduced neuritic plaque formation and Aβ levels in the brains of APP/PS1 mice, indicating thatAS-IV may be a promising agent for modulating Aβ-related pathology in AD. Expand
Dieckol Ameliorates Aβ Production via PI3K/Akt/GSK-3β Regulated APP Processing in SweAPP N2a Cell
The proteolytic processing of amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase releases amyloid-β peptide (Aβ), which deposits in amyloid plaques and contributes to the initialExpand
Glycyrrhiza uralensis and Semilicoisoflavone B Reduce A&bgr; Secretion by Increasing PPAR&ggr; Expression and Inhibiting STAT3 Phosphorylation to Inhibit BACE1 Expression
TLDR
Findings indicate that GUE and SB may function as PPARγ agonists, thereby inhibiting BACE1 expression and ultimately reducing the secretion of Aβ. Expand
Oxidative stress and expression of insulin signaling proteins in the brain of diabetic rats: Role of Nigella sativa oil and antidiabetic drugs
TLDR
NSO lowers the insulin receptor inhibitory effect of IOMe-AG538 and modifies the insulin-signaling pathway and prevents the neurotoxicity, amyloid plaque formation and Tau hyper-phosphorylation and restores AD-related miRNA normal levels. Expand
GLP-1’s role in neuroprotection: a systematic review
TLDR
Based on the preclinical studies, GLP-1 modifying agents are promising targets for neuroprotection and further clinical trials are needed for a benchside to bedside translation of recent findings. Expand
Subclinical Doses of ATP-Sensitive Potassium Channel Modulators Prevent Alterations in Memory and Synaptic Plasticity Induced by Amyloid-β.
TLDR
It is found that the protective effect of Tolbutamide against Aβ-induced memory deficit was strong and correlated with the reestablishment of synaptic plasticity balance, whereas Diazoxide treatment produced a mild protection against A β- induced memory deficit, which was not related to a complete re establishment of synaptic Plasticity balance. Expand
Investigating the Diabetic Brain: The Effects of Pioglitazone and Insulin on the Cellular Processes and Pathology of Alzheimer's Disease
TLDR
It is suggested that increasing glucose uptake in the brain alleviated AD pathology, further clarifying the role of insulin signaling in AD pathology. Expand
Totarol prevents neuronal injury in vitro and ameliorates brain ischemic stroke: Potential roles of Akt activation and HO-1 induction.
TLDR
Totarol prevented glutamate- and oxygen and glucose deprivation-induced neuronal death in primary rat cerebellar granule neuronal cells and cerebral cortical neurons and suggest that totarol may be a novel activator of the Akt/HO-1 pathway protecting against ischemic stroke through reduction of oxidative stress. Expand
A novel GSK-3β inhibitor YQ138 prevents neuronal injury induced by glutamate and brain ischemia through activation of the Nrf2 signaling pathway
TLDR
A novel GSK-3β inhibitor YQ138 effectively suppresses brain ischemic injury in vitro and in vivo and is found to exert neuroprotective effects. Expand
Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer’s Disease-Diabetes Dual Therapy
TLDR
The present computational and kinetics study concludes that glimepiride and other thiazolidinediones derivatives could form the basis of future dual therapy against diabetes associated neurological disorders. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 34 REFERENCES
Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription
TLDR
It is demonstrated that metformin, at doses that lead to activation of the AMP-activated protein kinase (AMPK), significantly increases the generation of both intracellular and extracellular Aβ species, suggesting a potentially harmful consequence of this widely prescribed antidiabetic drug when used as a monotherapy in elderly diabetic patients. Expand
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
TLDR
Ex-4 ameliorated the diabetic effects of STZ in 3xTg-AD mice, elevating plasma insulin and lowering both plasma glucose and hemoglobin A1c (HbA1c) levels and brain levels of Abeta protein precursor and Abeta were significantly reduced in Ex-4 treated mice. Expand
Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes.
TLDR
Results indicate that glimepiride has the potential to induce PPAR gamma activity, thereby improving insulin resistance, and is investigated on AMP-activated protein kinase and peroxisome proliferator-activated receptor-gamma activity. Expand
Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide
TLDR
It is confirmed that the Aβ clearance mechanism can indeed be induced by PPARγ activation in primary murine-mixed glia and cortical neuronal cultures, and suggested that PParγ-controlled mechanisms should be explored further as potential drug targets for Alzheimer's disease treatment. Expand
Sulfonylurea Agents Exhibit Peroxisome Proliferator-activated Receptor γ Agonistic Activity*
TLDR
The observation that glimepiride and glibenclamide could act not only on SU receptor but also on PPARγ may give an important clue to the development of novel antidiabetic drugs, which can enhance both insulin secretion from pancreatic β-cells and peripheral insulin sensitivity. Expand
Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ
TLDR
It is shown that PPARγ depletion potentiates β-secretase [β-site amyloid precursor protein cleaving enzyme (BACE1)] mRNA levels by increasing BACE1 gene promoter activity, and suggest that the protective mechanism of NSAIDs in AD involves activation of PPARαγ and decreased Bace1 gene transcription. Expand
Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity.
TLDR
The observation that glimepiride and glibenclamide could act not only on SU receptor but also on PPARgamma may give an important clue to the development of novel antidiabetic drugs, which can enhance both insulin secretion from pancreatic beta-cells and peripheral insulin sensitivity. Expand
The Role of Peroxisome Proliferator-Activated Receptor-γ PPARγ) in Alzheimer’s Disease
TLDR
PPARγ may act to modulate multiple pathophysiological mechanisms that contribute to Alzheimer’s disease, and represents an attractive therapeutic target for the treatment of the disease. Expand
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
TLDR
It is demonstrated that pioglitazone exhibited cognitive and functional improvements, and stabilization of the disease in diabetic patients with AD, and may offer a novel strategy for the treatment of AD. Expand
Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
Background Sulfonylurea primarily stimulates insulin secretion by binding to its receptor on the pancreatic β-cells. Recent studies have suggested that sulfonylureas induce insulin sensitivityExpand
...
1
2
3
4
...